Anti-BCMA antibodies in the future management of multiple myeloma

References

• Laabi Y, Gras MP, Carbonnel F, et al. A new gene, BCM, on chromosome 16 is fused to interleukin 2 gene by a t(4;16)(q26;p13) translocation in a malignant T cell lymphoma. Embo J. 1992;11:3897–3904.
   PubMed Web of Science ®Google Scholar
• Laabi Y, Gras MP, Brouet JC, et al. The BCMA gene, preferentially expressed during lymphoid maturation, is bidirectionally transcribed. Nucleic Acids Res. 1994;22:1147–1154.
   PubMed Web of Science ®Google Scholar
• Novak AJ, Darce JR, Arendt BK, et al. Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood. 2004;103:689–694.
   PubMed Web of Science ®Google Scholar
• Thompson JS, Schneider P, Kalled SL, et al. BAFF binds to the tumor necrosis factor receptor- like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population. J Exp Med. 2000;192:129–135.
   PubMed Web of Science ®Google Scholar
• Seckinger A, Delgado JA, Moser S, et al. Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment. Cancer Cell. 2017;31:396–410.
   PubMed Web of Science ®Google Scholar
• Sanchez E, Li M, Kitto A, et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol. 2012;158:727–738.
   PubMed Web of Science ®Google Scholar
• Pelletier M, Thompson JS, Qian F, et al. Comparison of soluble decoy IgG fusion proteins of BAFF-R and BCMA as antagonists for BAFF. J Biol Chem. 2003;278:33127–33133.
   PubMed Web of Science ®Google Scholar
• Rennert P, Schneider P, Cachero TG, et al. A soluble form of B cell maturation antigen, a receptor for the tumor necrosis family member APRIL inhibits solid tumor growth, however, in hematological malignancies, APRIL stimulates growth. J Exp Med. 2000;192:1677–1683.
   PubMed Web of Science ®Google Scholar
• Schneider P, Mackay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999;199:1747–1756.
   Google Scholar
• Yan M, Marsters SA, Grewal IS, et al. Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity. Nat Immunol. 2000;1:37–41.
   PubMed Web of Science ®Google Scholar
• Schneider P, Takatsuka H, Wilson A, et al. Maturation of marginal zone and follicular B cells requires B cell activating factor of the tumor necrosis factor family and is independent of B cell maturation antigen. J Exp Med. 2001;194:1691–1697.
   PubMed Web of Science ®Google Scholar
• Moore PA, Belvedere O, Orr A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999;285:260–263.
   PubMed Web of Science ®Google Scholar
• Mackay F, Jl B. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol. 2002;2(7):465–475.
   PubMed Web of Science ®Google Scholar
• Avery DT, Kalled SL, Ellyard JI, et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest. 2003;112:286–297.
   PubMed Web of Science ®Google Scholar
• Tai Y-T, Acharya C, An G, et al. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood. 2016;127:3225–3236.
   PubMed Web of Science ®Google Scholar
• Moreaux J, Legouffe E, Jourdan E, et al. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone. Blood. 2004;103:3148–3157.
   PubMed Web of Science ®Google Scholar
• Chen H, Li M, Sanchez E, et al. Gene expression of Gamma Secretase (GS) complex-related proteins, the enzyme that sheds B-Cell Maturation Antigen (BCMA), among patients with Multiple Myeloma (MM) and effects of the GS Inhibitor LSN424354 on solubilized bcma in MM and chronic lymphocytic leukemia. Blood. 2016;128:5641.
   Web of Science ®Google Scholar
• Sanchez E, Gillespie AE, Tang G, et al. Soluble B-cell maturation antigen mediates tumor- induced immune deficiency in multiple myeloma. Clin Cancer Res. 2016;22:3383–3397.
   PubMed Web of Science ®Google Scholar
• Mariani G, Strober W. Immunoglobulin metabolism. In: Metzger H, editor. Fc receptors and the action of antibodies. Am Soc Microbiol. 1990. p. 94–190.
   Google Scholar
• Anderson CL, Chaudhury C, Kim J, et al. Perspective – FcRn transports albumin: relevance to immunology and medicine. Trends Immunol. 2006;27:343–348.
   PubMed Web of Science ®Google Scholar
• Udd KA, Soof C, Etessami S, et al. Changes in serum B-cell maturation antigen levels are a rapid and reliable indicator of treatment efficacy for patients with multiple myeloma. Poster session presented at: 16th International Myeloma Workshop; 2017 Mar 1– 4;New Delhi, India.
   Google Scholar
• Bujarski S, Udd K, Soof C, et al. Changes in serum B-cell maturation antigen levels rapidly indicate changes in clinical status among multiple myeloma patients undergoing new treatments. Poster session presented at: myeloma: Biology and Pathophysiology, excluding Therapy. 59th ASH Annual Meeting and Exposition; 2017 Dec 9–12; Atlanta, GA.
   Google Scholar
• Jagannath S. Value of free light chain testing for the diagnosis and monitoring of monoclonal gammopathies in hematology. Clin Lymphoma Myeloma. 2007;7(8):519–523.
   Google Scholar
• Alyanakian MA, Abbas A, Delarue R, et al. Free immunoglobulin light-chain serum levels in the follow up of patients with monoclonal gammopathies: correlation with 24-hr urinary light-chain excretion. Am J Hematol. 2004;75:246–248.
   PubMed Web of Science ®Google Scholar
• Ghermezi M, Li M, Vardanyan S, et al. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica. 2017;102:785–795.
   PubMed Web of Science ®Google Scholar
• Gross JA, Johnston J, Mudri S, et al. TACI and BCMA are receptors for a TNF homologue implicated in B cell autoimmune disease. Nature. 2000;404:995–999.
   PubMed Web of Science ®Google Scholar
• Hong-Bing S, Johnson H. B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1. PNAS. 2000;97:9156–9161.
   PubMed Web of Science ®Google Scholar
• Ryan MC, Hering M, Peckham D, et al. Antibody targeting of B-cell maturation antigen on malignant plasma cells. Mol Cancer Ther. 2007;6:3009–3019.
   PubMed Web of Science ®Google Scholar
• Tai Y-T, Mayes PA, Chirag A, et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014;123:3128–3138.
   PubMed Web of Science ®Google Scholar
• Cohen AD, Popat R, Trudel S. First in human study with GSK2857916, an antibody drug conjugated to microtubule-disrupting agent directed against B-Cell Maturation Antigen (BCMA) in patients with relapsed/refractory Multiple Myeloma (MM): results from study BMA117159 Part 1 dose escalation. Blood. 2016;128:1148.
   Web of Science ®Google Scholar
• Trudel S, Md L, Popat NR, et al. Targeting B-cell maturation antigen with GSK2857917 antobody-drug conjugate in relapsed or refractory multiple myeloma (BMA1171159): a dose escalation and expansion phase 1 trial. Lancet Oncol. 2018 Dec;19(12):1641–1653.
   PubMed Web of Science ®Google Scholar
• Hipp S, Tai Y-T, Blanset D, et al. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia. 2017;31:1743–1751.
   PubMed Web of Science ®Google Scholar
• Topp MS, Due J, Zugmaie G et al. Treatment with AMG 420, an anti-B-Cell Maturation Antigen (BCMA) bispecific T-cell engager (BiTE®) antibody construct, induces Minimal Residual Disease (MRD) negative complete responses in Relapsed and/or Refractory (R/R) Multiple Myeloma (MM) patients: results of a First-in-Human (FIH) Phase I dose escalation study Abstract no 1010 60th Annual Meeting, ASH 2018, 1–4 Dec, San Diego, California
   Google Scholar
• Ramadoss NS, Schulman AD, Choi S-H, et al. An anti-B cell maturation antigen bispecific antibody for multiple myeloma. J Am Chem Soc. 2015;137:5288–5291.
   PubMed Web of Science ®Google Scholar
• Law CL, Aaron W, Austin R et al. Preclinical and nonclinical characterization of HPN217: A Tri-Specific T Cell Activating Construct (TriTAC) targeting B Cell Maturation Antigen (BCMA) for the treatment of multiple myeloma Abstract no 3225, 60th Annual Meeting, ASH 2018, 1–4 Dec, San Diego, California
   Google Scholar
• Ross T, Reusch U, Wingert S et al. Preclinical characterization of AFM26, a novel B Cell Maturation Antigen (BCMA)-directed tetravalent bispecific antibody for high affinity retargeting of NK cells against myeloma Abstract no 1927, 60th Annual Meeting, ASH 2018, 1–4 Dec, San Diego, California
   Google Scholar
• Dilillo DJ, Olson K, Mohrs K et al. REGN5458, a Bispecific BCMAxCD3 T cell engaging antibody, demonstrates robust in vitro and in vivo anti-tumor efficacy in multiple myeloma models, comparable to that of BCMA CAR T cells Abstract no 1944, 60th Annual Meeting, ASH 2018, 1–4 Dec, San Diego, California
   Google Scholar
• Lesokhin A, Raje N, Gasparetto CJ et al. A phase I, open-label study to evaluate the safety, pharmacokinetic, pharmacodynamic, and clinical activity of PF-06863135, a B-Cell Maturation Antigen/cd3 bispecific antibody, in patients with relapsed/refractory advanced multiple myeloma Abstract no 3229 60th Annual Meeting, ASH 2018, 1–4 Dec, San Diego, California
   Google Scholar
• Carpenter RO, Evbuomwan MO, Pittaluga S, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res. 2013;19:2048–2060.
   PubMed Web of Science ®Google Scholar
• Ali SA, Shi V, Maric I, et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood. 2016 Sep 29;128(13):1688–1700.
   PubMed Web of Science ®Google Scholar
• Raje NS, Berdeja JG, Lin Y, et al. bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: updated results from a multicenter phase I study. J Clin Oncol. 2018;36(suppl; abstr 8007).
   Google Scholar
• Shah N, Alsina M, Siegel DS et al. Initial results from a Phase 1 clinical study of bb21217, a next-generation anti BCMA CAR T therapy abstract no 488, 60th Annual Meeting, ASH 2018, 1–4 Dec, San Diego, California
   Google Scholar
• Fan F, Zhao W, Liu J, et al. Durable remissions with BCMA-specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma. Session presented at: 53rd American Society of Clinical Oncology Annual Meeting; 2017 Jun 2–6; Chicago, IL.
   Google Scholar
• Zhao WH, Liu J, Wang BY, et al. Updated analysis of a Phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B-Cell Maturation Antigen, in patients with relapsed/refractory multiple myeloma, Abstract no 955, 60th Annual Meeting, ASH 2018, 1–4 Dec, San Diego, California
   Google Scholar
• Mailankody S, Ghosh A, Staehr M, et al. Clinical responses and pharmacokinetics of MCARH171, a human-derived BCMA targeted CAR T cell therapy in relapsed/refractory multiple myeloma: final results of a Phase I clinical trial Abstract no 959, 60th Annual Meeting, ASH 2018, 1–4 Dec, San Diego, California
   Google Scholar
• Green D, Pont M, Sather BD, et al. Fully human BCMA targeted chimeric antigen receptor T cells administered in a defined composition demonstrate potency at low doses in advanced stage high risk multiple myeloma Abstract no 1011, 60th Annual Meeting, ASH 2018, 1–4 Dec, San Diego, California
   Google Scholar
• Gregory T, Cohen A, Costello CL et al. Efficacy and safety of P-BCMA-101 CAR-T cells in patients with relapsed/refractory (r/r) Multiple Myeloma (MM). Abstract no 1012, 60th Annual Meeting, ASH 2018, 1–4 Dec, San Diego, California
   Google Scholar
• Mailankody S, Htut M, Lee KP, et al. JCARH125, anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma: initial proof of concept results from a phase 1/2 multicenter study (EVOLVE). Abstract no 957, 60th Annual Meeting, ASH 2018, 1–4 Dec, San Diego, California
   Google Scholar
• Sommer C, Boldajipour B, Valton J et al. ALLO-715, an allogeneic BCMA CAR T therapy possessing an off-switch for the treatment of multiple myeloma, Abstract no 591, 60th Annual Meeting, ASH 2018, 1–4 Dec, San Diego, California
   Google Scholar
• Tai YT, Dulos J, Guelen L et al. APRIL is significantly elevated at all stages of Multiple Myeloma (MM) and interferes with anti-BCMA monoclonal antibody-mediated cytolysis, supporting the clinical evaluation of bion-1301 as a novel therapeutic approach in MM Abstract no 3209 Annual Meeting, ASH 2018, 1–4 Dec, San Diego, California
   Google Scholar
• Singh RK, Jones RJ, Hong S HDP101, a novel B-Cell Maturation Antigen (BCMA)-targeted antibody conjugated to α-Amanitin, is active against myeloma with preferential efficacy against pre-clinical models of deletion 17p Abstract no 593 Annual Meeting, ASH 2018, 1–4 Dec, San Diego, California
   Google Scholar
• Sanchez E, Ej T, Patil S, et al. The clinical significance of B-cell maturation antigen as a therapeutic target and biomarker. Expert Rev Mol Diagn. 2018 Apr;18((4):):319–329.
   PubMed Web of Science ®Google Scholar